HSBC Holdings’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
Other funds holding CCCC
LCM
HSBC Holdings's CCCC Position: Q3 2026 in Review
HSBC Holdings sold out of C4 Therapeutics (CCCC) in Q3 2026, closing a stake of 13,629 shares — an estimated $70.3K sold.
HSBC Holdings first reported a position in CCCC in Q1 2022 and held it in 14 quarters. The position peaked at $251K in Q1 2022. 152 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.
- HSBC Holdings reported no remaining C4 Therapeutics position as of Q3 2026 after selling out during the quarter.
- HSBC Holdings sold 13,629 C4 Therapeutics shares in Q3 2026, an estimated $70.3K.
- HSBC Holdings first reported a position in C4 Therapeutics in Q1 2022 and held it in 14 quarters.
- HSBC Holdings's C4 Therapeutics position peaked at $251K in Q1 2022.
- 152 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.
Based on HSBC Holdings's 13F filing for Q3 2026, filed 16 Nov 2026.